Hae Won Lee, Gi‐Won Song, Sung‐Gyu Lee, Jong Man Kim, Jae‐Won Joh, Dai Hoon Han, Soon Il Kim, Seong Hoon Kim, Dong‐Sik Kim, Jai Young Cho, Kyung‐Suk Suh – 25 March 2018 – Although far advanced hepatocellular carcinoma (HCC) is generally considered a contraindication for liver transplantation (LT), biologically favorable tumors among them could show acceptable results. However, it is still unclear which tumors can be treated with LT. Data were collected on adult patients who underwent LT for HCC beyond the Milan criteria in 8 Korean LT centers between January 2000 and June 2013.

Junaid Beig, David Orr, Barry Harrison, Edward Gane – 25 March 2018 – Interferon (IFN)‐free, direct‐acting antiviral (DAA) therapy agents provide a safe and efficacious treatment for liver transplant recipients with recurrent hepatitis C virus (HCV) infection. The aim of this study is to evaluate the impact of HCV eradication on the metabolic factors in liver transplant recipients. We completed a retrospective single‐center study on HCV‐related liver transplant recipients treated with IFN‐free DAAs including both treatment‐naive and treatment‐experienced patients.

25 March 2018

Cyriel Y. Ponsioen, Keith D. Lindor, Ruby Mehta, Lara Dimick‐Santos – 25 March 2018 – Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease.

Rachel Niec, Robert E. Schwartz, Russell Rosenblatt, Vikas Gupta, Zaid H. Tafesh, Robert S. Brown, Nicholas Russo, Shirley Cohen‐Mekelburg, Saurabh Mukewar, Aleksey Novikov – 25 March 2018

Rachel Niec, Robert E. Schwartz, Russell Rosenblatt, Vikas Gupta, Zaid H. Tafesh, Robert S. Brown, Nicholas Russo, Shirley Cohen‐Mekelburg, Saurabh Mukewar, Aleksey Novikov – 25 March 2018

25 March 2018

25 March 2018

25 March 2018

Cyriel Y. Ponsioen, Keith D. Lindor, Ruby Mehta, Lara Dimick‐Santos – 25 March 2018 – Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease.